Translate
Bridgebio Pharma, Inc.
About
69.12USD-1.16 -1.65%
Closed • Updated at 13:08 GMT+00:00Market Cap$13.54B
Volume1.83M
Beta0.13
RSI49.27
Gross Margin94.69%
Bridgebio Pharma, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 12 2026
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
May 7 2026
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
May 6 2026
BridgeBio to Participate in May and June Investor Conferences
May 6 2026
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
May 5 2026
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
Recent Videos
Warren K Lewis Lecture, May 1, 2026
May 13, 2026
Bridgebio Pharma Inc. 2026 quarterly report
May 13, 2026
BridgeBio (BBIO|$13.5B) - 2026 Q1 Earnings Analysis
May 08, 2026
The Problem-to-Execution Pipeline: AI Meets Expert Consulting 💡
Apr 29, 2026
Community Chat
Ask AI
Try asking